Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2025 Jul 1.
Published in final edited form as: J Addict Med. 2025 Mar 11;19(5):507–509. doi: 10.1097/ADM.0000000000001452

Oral Health Risks of Transmucosal Buprenorphine: Commentary on Tuan et al. and Zheng et al

Anne C Black 1, William C Becker 1
PMCID: PMC12210154  NIHMSID: NIHMS2088347  PMID: 40066875

Abstract

Opioid use disorder affects millions of people nationally and in 2022 opioid overdose deaths exceeded 80,000. Buprenorphine, a partial mu-opioid receptor agonist, is a gold standard treatment for opioid use disorder, improving withdrawal symptoms and decreasing opioid-related mortality. However, a 2022 Food and Drug Administration warning about oral health problems related to transmucosal formulations has precipitated new research into this medication’s potential risks. Two timely studies included in this issue of Journal of Addiction Medicine provide important new insight into potential causal effects and mechanisms of transmucosal buprenorphine’s impact on oral disease. Using propensity score–weighted survival analysis, Tuan and colleagues demonstrated significantly greater risk for oral health problems in patients with opioid use disorder exposed to transmucosal buprenorphine compared to those not exposed. Taking a vastly different approach, Zheng and colleagues explored mechanisms of oral health risk by exposing rats to transmucosal or intravenous buprenorphine. Results described prolonged oral fluid buprenorphine exposure, a condition proposed to increase risk for tooth decay, was associated with greater accumulated buprenorphine in the salivary gland associated with sublingual buprenorphine administration. These novel studies advance our understanding of the plausibility of a causal relationship between transmucosal buprenorphine and oral health problems and suggest the importance of prescriberpatient discussions about risk mitigating oral hygiene practices and close monitoring of oral disease development. Additional research is needed into the relative oral health risks of full-opioid agonist versus transmucosal buprenorphine exposure and current barriers to long-acting injectable buprenorphine.

Keywords: buprenorphine, opioid use disorder, long-term opioid therapy, oral health, dental disease


The opioid crisis continues to threaten the lives and well-being of individuals and families in the United States. In 2022, approximately 6.1 million people aged 12 and over reported having an opioid use disorder (OUD) in the past year, and opioid-related deaths exceeded 80,000.1,2 Buprenorphine is a gold standard treatment for OUD with evidence supporting its superior safety and effectiveness compared to other OUD treatment options.3 A partial mu-opioid receptor agonist, buprenorphine effectively treats opioid withdrawal symptoms and is associated with reduced opioid-related mortality.4,5 However, the most common formulations of buprenorphine for OUD, including buccal and sublingual formulations (tablets and sublingual film), may also pose risk for oral disease. In January 2022, the US Food and Drug Administration (FDA) released a warning about dental problems associated with transmucosal buprenorphine (TMB),6 including tooth decay, cavities, infections, and tooth loss manifesting 2 weeks to several years after buprenorphine exposure. However, the anecdotal nature of the approximately 300 case reports supporting the warning raised questions about attributable risk—defined as the proportion of the disease occurrence that can be attributed to a certain exposure of TMB—that subsequent studies have sought to elucidate. Simultaneously, lawsuits against the manufacturers of suboxone have mounted nationally with claims of dental harms. Several treatment societies have asked for retraction of the FDA warning, noting concerns about its potential impact on use of a life-saving treatment.7 The effects of FDA’s warning on buprenorphine prescribing practices are as yet unclear, occurring in the context of X-waiver exemptions, ultimate X-waiver elimination in January 2023, and other national initiatives designed to remove barriers to buprenorphine access. Critically, the FDA warning declared that benefits of buprenorphine use clearly outweigh the oral health risks.

A 2022 a retrospective cohort study by Etminan and colleagues8 of over 21,000 new users of sublingual buprenorphine/naloxone demonstrated greater TMB-associated oral health risks, including dental caries and tooth loss, relative to transdermal buprenorphine or oral naltrexone. Omission of patient oral hygiene information and inability to determine indication for prescriptions—exposing the possibility that some patients might have been treated for chronic pain without OUD—were noted as primary limitations. The study’s sampling strategy and conclusions drew criticism and concern about the potential impact of misinterpreted results on practice.9 Clear evidence for a causal effect of TMB has remained elusive to date in the absence of more rigorous study designs including randomized controlled trials.

Two studies reported in this issue of Journal of Addiction Medicine contribute importantly and uniquely to our evolving understanding of the oral health risks of TMB, one applying a rigorous quasi-experimental design that takes us a step closer to causal conclusions and the other, a thoughtful, sequential exploration of potential mechanisms of TMB-associated harm conducted in rats. In their paper, “Risk of oral health problems in adults with OUD treated with transmucosal buprenorphine,” Tuan and colleagues address 2 primary weaknesses identified by Etminan and colleagues by including in the calculation of propensity score weights an array of covariates accounting for differences in oral health and TMB exposure, including preexisting oral health diagnoses and healthcare utilization. Models leveraged a global insurance claims dataset including over 700,000 adults diagnosed with OUD, 22% of whom had sustained exposure to TMB. In propensity score–weighted survival models, results supported greater risk for adverse oral health outcomes for TMB-exposed patients compared to unexposed. Greater risk for oral health problems was observed as early as 1 month following TMB initiation. An accumulated dose-associated increase in risk was demonstrated in a sensitivity analysis restricted to patients with longer-term TMB exposure. These results are especially timely in the context of buprenorphine prescribing in the fentanyl era, where greater effectiveness of buprenorphine has been observed with higher doses (ie, > 16 mg and > 24 mg) for some outcomes, particularly for patients in treatment for fentanyl-associated OUD. High-dose TMB may be needed to block the effects of ultra-high potency and high affinity opioids by reducing mu-opioid receptor availability.10 In these cases, prescribers may need to monitor the development of oral health problems more frequently and risk-mitigating measures including oral healthcare guidelines may be especially relevant.

The second paper in this issue by Zheng (Hu, contact and senior author) and colleagues, “Buprenorphine salivary gland accumulation sustaining high oral fluid exposure and increasing the risk of Streptococcus mutans biofilm formation,” explores the mechanisms by which TMB exposure may pose oral health risks. In female rats administered TMB (sublingual buprenorphine film; n = 4) or intravenous buprenorphine (n = 3), the authors explored the relationship between the salivary gland, oral fluid, and blood exposure in accounting for prolonged oral fluid buprenorphine exposure, a condition proposed to increase risk for biofilm formation of Streptococcus mutans, the primary agent in tooth decay. The authors identified the relevance of accumulated buprenorphine in the salivary gland, associated with sublingual buprenorphine administration.

Applying advanced quasi-experimental and mechanism-exploring methods, these 2 studies distinctly advance the plausibility of a causal relationship between TMB and oral health problems that underscores the urgency of testing risk-mitigating measures.

FUTURE RESEARCH

In light of the developing evidence, it is critical for patients and clinicians to understand how readily TMB-associated oral health risk can be mitigated. Manufacturers of buprenorphine may consider altering the tablet or film composition to be less acidic, which may reduce infection risk. In addition, the impact of mouth rinse after administration or increased tooth brushing frequency, as prescribed in the FDA warning, should be studied. The extent to which patients can adhere to these guidelines and the relative effectiveness of strict versus poorer adherence for oral health risk management warrants examination.

Buprenorphine may paradoxically help improve oral health in people with OUD by ameliorating a range of challenges to oral hygiene and health-promoting behaviors associated with opioid misuse. Poor nutritional habits, malnutrition, and OUD-associated social consequences such as homelessness and food insecurity pose significant barriers to oral health and other positive behavioral routines11 that may be mitigated by buprenorphine treatment. As improved oral hygiene would have myriad benefits for patients, research in this area is urgently warranted.

Direct comparisons showing comparable outcomes for long-acting injectable buprenorphine (LAIB) relative to TMB suggest LAIB may be a viable treatment alternative for patients at high risk for oral health problems, including patients exposed to fentanyl who may require higher sublingual doses. LAIB, first approved by the FDA in 2017, also presents the advantage of less frequent dosing, addressing a barrier of TMB’s daily administration. Post hoc comparisons from a randomized controlled trial comparing LAIB to TMB showed notable, but underpowered, group differences favoring the former for urine samples negative for any opioid. Both buprenorphine treatments were effective in reducing opioid withdrawal and cravings, but LAIB was superior to TMB for urine samples negative for fentanyl among patients who were fentanyl-exposed.12 However, LAIB requires highly regulated clinician administration, which means another trade-off to consider—giving up the convenience of a selfadministered film to avoid further worsening of oral disease—when it is possible that a less burdensome maneuver—improved oral hygiene—would reduce the risk just as much or possibly more, than a switch to LAIB.

A common clinical scenario faced by our group and others involves the decision to switch to buprenorphine when patients prescribed long-term full opioid agonist therapy (LTOT) (≥ 90 days of continuous opioid prescription allowing for 30-day refill gaps) develop OUD. The relative oral health risks of TMB versus LTOT are not well known, highlighting another critical gap warranting examination. Commonly prescribed full opioid agonists such as hydrocodone and oxycodone are known to cause xerostomia13 and can impair immune function,14 both of which may promote dental caries, tooth decay and tooth loss, and these effects may be dose dependent. Furthermore, full opioid agonists are associated with hypogonadism and osteoporosis,15 which can cause dental problems. Warnings about the oral health risks of TMB could deter patients from switching away from LTOT, leaving them at unknown risk for the same negative oral health outcomes.

CONCLUSIONS

Critical evidence is accumulating in support of a 2022 FDA warning about the oral health risks of TMB, suggesting greater risk for adverse outcomes for patients exposed to TMB compared to no exposure, or exposure to other buprenorphine formulations for OUD. In light of buprenorphine’s unequivocal benefits for OUD management including reduced mortality in an era where 10,000 of patients are lost to opioid overdose death each year, this mounting evidence creates the need for more research into oral health risk-mitigation measures. Promising but understudied options include oral healthcare in the context of TMB therapy and reducing barriers to implementation of LAIB as an alternative formulation. The relative risks of full agonist versus partial agonist opioids remain unexplored, and evidence regarding this comparison could address a high-risk barrier to patients’ switching from LTOT when indicated. The studies included in this issue of JAM take us a step closer to understanding buprenorphine’s risk and potential solutions for safer OUD treatment.

Acknowledgments

Supported by the National Institute on Drug Abuse of the National Institutes of Health under Award Number RM1DA055310 and 1U24DA058673. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Footnotes

The authors report no conflicts of interest.

This is original contribution not previously published nor under consideration for publication elsewhere. If accepted, it will not be published elsewhere in similar form, in any language, without the consent of Lippincott Williams & Wilkins. Each author participated in the preparation of this work to a significant extent.

REFERENCES

  • 1.Substance Abuse and Mental Health Services Administration. Key Substance Use and Mental Health Indicators in the United States: Results From the 2018 National Survey on Drug Use and Health (HHS Publication No. PEP19-5068, NSDUH Series H-54). Rockville, MD: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration, 2019. Accessed November 6, 2024. https://www.samhsa.gov/data/. [Google Scholar]
  • 2.CDC. Provisional drug overdose data. CDC: 2024. Accessed November 11, 2024. https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm [Google Scholar]
  • 3.Mariolis T, Bosse J, Martin S, et al. A systematic review of the effectiveness of buprenorphine for opioid use disorder compared to other treatments: Implications for research and practice. J Addict Res Ther. 2019;10:379. [Google Scholar]
  • 4.Gowing L, Ali R, White JM. Buprenorphine for the management of opioid withdrawal. Cochrane Database Syst Rev. 2009;3:CD002025. [DOI] [PubMed] [Google Scholar]
  • 5.Larochelle MR, Bernson D, Land T, et al. Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: A cohort study. Annals Intl Med. 2018;169:137–145. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Knopf A. FDA warns about dental problems with buprenorphine medicines dissolved in the mouth. Brown Univ Child Adolescent Psychopharmacol Update. 2022;24:8. [Google Scholar]
  • 7.American Academy of Addiction Psychiatry, American College of Academic Addiction Medicine, American College of Medical Toxicology, et al. Re: A call for the FDA to retract its safety communication regarding buprenorphine. Published January 24, 2022. Accessed November 6, 2024. https://amersa.org/wp-content/uploads/22.01.24%20A%20Call%20for%20the%20FDA%20to%20Retract%20its%201.12.2022%20Safety%20Communication%20Regarding%20Buprenorphine.pdf
  • 8.Etminan M, Rezaeianzadeh R, Kezouh A, et al. Association between sublingual buprenorphine-naloxone exposure and dental disease. JAMA. 2022;328:2269–2271. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Etminan M, Rezaeianzadeh R. Sublingual buprenorphine-naloxone exposure and dental disease—Reply. JAMA. 2023;329:1224–1225. [DOI] [PubMed] [Google Scholar]
  • 10.Greenwald MK, Comer SD, Fiellin DA. Buprenorphine maintenance and mu-opioid receptor availability in the treatment of opioid use disorder: Implications for clinical use and policy. Drug Alcohol Depend. 2014;144:1–11. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Chavez MN, Rigg KK. Nutritional implications of opioid use disorder: A guide for drug treatment providers. Psychol Addict Behav. 2020;34:699–707. [DOI] [PubMed] [Google Scholar]
  • 12.Nunes EV, Comer SD, Lofwall MR, et al. Extended-release injection vs sublingual buprenorphine for opioid use disorder with fentanyl use: A post hoc analysis of a randomized clinical trial. JAMA Netw Open. 2024;7:e2417377–e2417377. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Götrick B, Åkerman S, Ericson D, et al. Oral pilocarpine for treatment of opioid-induced oral dryness in healthy adults. J Dent Res. 2004;83:393–397. [DOI] [PubMed] [Google Scholar]
  • 14.Ninković J, Roy S. Role of the mu-opioid receptor in opioid modulation of immune function. Amino Acids. 2013;45:9–24. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Daniell HW. Opioid osteoporosis. Arch Intern Med. 2004;164:338–338. [DOI] [PubMed] [Google Scholar]

RESOURCES